Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer
SAN DIEGO, CA (June 7, 2007) Zogenix, Inc., a privately held CNS-focused specialty pharmaceutical company, announced today that David Nassif has been appointed Executive Vice President and Chief Financial Officer.
Mr. Nassif brings a breadth of life science experience across multiple roles, including financial planning, investor relations, SEC reporting, debt and equity financings, mergers and acquisitions, business and corporate development, treasury activities, legal affairs and the corporate secretary function. Mr. Nassif has more than 14 years of industry experience in executive financial management roles in both development-stage and commercial-stage companies with both public and private companies.
Before joining Zogenix, Mr. Nassif was a consultant to the Company after leaving Amphastar Pharmaceucticals, Inc. as its Chief Financial Officer and Senior Vice President of Global Licensing. During his 4 years at Amphastar, Mr. Nassif led the acquisition of the U.S and Canadian rights to a high-margin, marketed product, acquired another pharmaceutical company and completed a corporate partnership with Andrx Corporation around the Company’s lead pipeline product. These transactions culminated in the filing of an initial public offering for Amphastar in 2005.
“David brings a wealth of knowledge and experience to our management team,” said Roger Hawley, Zogenix’s chief executive officer. “Even before joining us full-time, he led our $10 million debt financing with GE Healthcare Financial Services. He will lead our future financing programs. He will work closely with our Board of Directors and our various Board committees. He will be an excellent complement to our commercial and business development teams as we build our commercial organization and move quickly toward the launch of our first product, sumatriptan Intraject®.”
About Zogenix, Inc.
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a private, specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. The company’s initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject® - a needle-free, single-use, disposable, and easy-to-use subcutaneous delivery system for sumatriptan that will compete in the $2.5 billion triptan segment of the migraine market. Additional information on the company can be found at www.zogenix.com.
Intraject is a registered trademark of Zogenix, Inc.
VP, Commercial Strategy & Corporate Communications
858-436-8595 or firstname.lastname@example.org
415-821-2413 or email@example.com